AdaptHealth stock
AHCONASDAQAdaptHealth Corp., HealthcareISIN US00653Q1022
32Score 32 out of 100, Weak
Price and trend
47 / 100
Price history
−16% in one yearThe chart shows daily closes over 8 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 13% below it.
Since July 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Overheated: the price has risen very quickly lately (RSI 83).
The price is 41% below its 52-week high. Largest decline in 8 years: 87% (February 2021 to August 2026).
Chart figures for advanced users
- SMA 50$6.16
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$9.05
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)83
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$5.22
- The lowest closing price of the last twelve months.
- Resistance$13.38
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- AdaptHealth Corp. belongs to the Medical (Devices) industry (United States) and, with a market value of $1.07B, is number 58 of 88 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $3.24B (down 0.5% year on year) and a loss of $70.79M.
- For fiscal 2026, analysts expect on average revenue of $2.91B (down 10.4%) and adjusted earnings per share of −$0.16.
Show more
- MEQIRI Score 32 out of 100 (Weak): rank 655 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 25.2% a year since 2020, Medical (Devices) median 13.8%.Growth 58
Weaknesses
- DilutionShare count up 157% since 2020.Capital allocation 18
- Interest barely coveredOperating profit covers interest only 0.9 times.Stability 30
- Loss-makingLoss of $406.73M over the last 12 months.Fundamentals 34
The score is held back by profitability and valuation.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 33 to 32.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high price swings
- weak fundamentals
- price far below its 52-week high
Valuation
Valuation signal
OvervaluedA fair value is not meaningful here, so the signal follows the valuation grade.
Valuation metrics
The model puts the fair value at less than a quarter of the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 19.8% on the twelve months before. Revenue has grown strongly since 2016, at around 38% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 18%, operating 6%, net −2%. Last 12 months: net −13%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 2 Mar 2027in 109 days
- Last reported
- 3 Nov 2026EPS reported −$0.18 (expected −$0.05)below expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 75.7% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$0.16+21.0%
- Revenue
- $2.91B+1.0%
- Earnings per share
- −$0.05−75.7%
- Revenue
- $2.99B+0.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook lowered
Share price after the results: −40.0%Full-year outlook reset: 2026 EBITDA now $490 to $520 million versus $680 to $730 million, due to divestitures, a large capitated contract ($55 million less) and a manufacturer price increase ($30 million).
“On a continuing operations basis, our full year EBITDA guidance is $490 million to $520 million, and let me bridge that to our prior guidance of $680 million to $730 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 4 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
2 insiders bought on the open market in the last 6 months, $520,530 in total. One insider sold, $231,138 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at AdaptHealth
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 32
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- Integra LifeSciences HoldingsIART $1.12B48
- Alphatec HoldingsATEC $1.1B34
- IRadimedIRMD $1.09B75
- SI-BONESIBN $1.09B47
- CeriBellCBLL $1.02B49
- ArtivionAORT $946.52M32
- Kuros BiosciencesKURN.SW $940.07M46
- OrthoPediatricsKIDS $850.68M47
ETFs that hold AdaptHealth
Held by 14 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Ageing Population UCITS ETF2B77 | 0.07% | 0.40% | €813.42M |
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.04% | 0.30% | €2.31B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.03% | 0.30% | €964.08M |
Show 5 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.03% | 0.30% | €4.28B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.03% | 0.30% | €185.82M |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.03% | 0.30% | €2.22B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.01% | 0.35% | €8.27B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.01% | 0.43% | €2.5B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 7 Aug 2026)
- Valuation signal Overvalued since 8 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.